MyFinsight
Home
Blog
About
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$891,608K
Free Cash flow
$23,992K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Gross proceeds from issuance of ...
Proceeds from sale of short-term...
Proceeds from maturity of short-...
Others
Negative Cash Flow Breakdown
Purchase of convertible senior n...
Repurchase of common stock
Purchases of short-term investme...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Impairment loss of financial royalty assets
-
-
6,197
0
Net income (loss)
48,508
-13,345
44,784
79,669
Gain on sale of pelican
-
-
-53,072
53,072
Loss from equity method investment in primrose bio
-
-
0
0
Change in estimated fair value of contingent liabilities
1,116
-624
615
-1,475
Gain on pelthos transaction
-
-
53,072
-
Depreciation of fixed assets and amortization of intangible assets
8,215
8,216
8,214
25,561
Accretion of short-term investments
1,199
1,502
2,015
2,943
Amortization of debt discount and issuance fees
823
803
565
708
Non-cash income from financial royalty assets
2,068
-4,796
7,372
1,248
Cecl adjustment to financial royalty assets
-222
21
-198
-724
(gain) loss on derivative instruments
1,369
-837
1,156
-134
Loss from change in fair value of equity-method investments and other investments
35,727
-49,229
14,783
75,887
Share-based compensation
13,653
10,596
14,270
32,579
Deferred income taxes, net
-12,983
13,532
-10,571
-12,113
(gain) loss from short-term investments
11,754
3,869
22,063
-3,630
Lease amortization expense
480
479
480
1,462
Other
-188
-547
-253
1,941
Accounts receivable
13,850
-6,409
2,087
19,650
Inventory
-3,003
4,140
-2,774
-2,214
Other economic rights
-
-
0
-
Accounts payable and accrued liabilities
3,246
2,714
7,345
-1,463
Income tax receivable and payable
173
-695
955
-3,622
Deferred revenue
0
0
0
-578
Cash outflow on deconsolidation of lnhc, inc
-
-
0
8,085
Other assets and liabilities
-773
-207
-2,212
6,099
Cash paid for investment in primrose bio
-
-
0
0
Net cash provided by (used in) operating activities
24,018
48,691
45,915
3,444
Cash paid for palvella notes receivable
-
-
-
0
Net cash paid for acquisitions
-
-
0
-
Acquisition of financial royalty assets
2,640
0
650
10,212
Cash paid for the agenus transaction
-
-
0
0
Acquisition of royalty receivables
-
-
0
813
Cash paid for apeiron acquisition, net of cash received
-
-
0
0
Proceeds from financial royalty assets
2,521
6,979
1,495
8,766
Cash paid for invios investment
-
-
303
0
Purchases of derivatives
2,672
0
5,113
8,679
Proceeds from sale of derivatives
614
431
0
-
Purchases of property and equipment
26
228
9
443
Purchases of short-term investments
37,148
222,179
211,857
514,856
Proceeds from sale of short-term investments
241,263
1,300
120,985
38,599
Proceeds from maturity of short-term investments
120,455
119,350
81,195
136,505
Purchases of other investments
1,250
-
3,847
-
Net cash provided by (used in) investing activities
321,117
-94,347
-18,104
-359,218
Gross proceeds from issuance of convertible senior notes
700,000
-
0
460,000
Debt discount and payment of debt issuance cost
20,125
50
617
14,911
Purchase of convertible senior notes hedge
195,790
-
0
113,250
Proceeds from issuance of warrants
114,100
-
0
67,390
Repurchase of common stock
60,000
-
0
15,000
Proceeds from common stock issuance, net of commissions and fees
-
-
0
0
Repayment of 2023 notes at maturity
-
-
0
-
Payments under finance lease obligations
7
7
7
20
Payments to cvr holders
-
-
0
174
Net proceeds from stock option exercises and espp
8,601
7,654
9,298
38,203
Taxes paid related to net share settlement of equity awards
345
21,730
344
9,255
Proceeds from pelthos investors
0
-
0
6,910
Net cash provided by financing activities
546,434
-14,133
8,330
419,893
Effect of exchange rate changes on cash and cash equivalents
39
-44
-590
2,950
Net increase (decrease) in cash, cash equivalents and restricted cash, including cash and cash equivalents classified within assets held for sale
891,608
-126,902
-
71,707
Less net increase in cash and cash equivalents classified within assets held for sale
0
2,817
-
-
Net increase (decrease) in cash, cash equivalents and restricted cash
891,608
-59,833
102,620
-
Cash, cash equivalents and restricted cash at beginning of period
115,094
174,927
139,376
72,307
Cash, cash equivalents and restricted cash at end of period
1,006,702
115,094
174,927
139,376
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Gross proceeds from
issuance of convertible...
$700,000K
Proceeds from sale of
short-term investments
$241,263K
Proceeds from maturity of
short-term investments
$120,455K
Net income (loss)
$48,508K
Proceeds from issuance of
warrants
$114,100K
Net proceeds from
stock option...
$8,601K
Proceeds from financial
royalty assets
$2,521K
Proceeds from sale of
derivatives
$614K
Share-based compensation
$13,653K
Deferred income taxes,
net
-$12,983K
Depreciation of fixed assets
and amortization of...
$8,215K
Accounts payable and
accrued liabilities
$3,246K
Inventory
-$3,003K
Amortization of debt discount
and issuance fees
$823K
Other assets and
liabilities
-$773K
Lease amortization
expense
$480K
Net cash provided by
financing activities
$546,434K
Net cash provided by
(used in) investing...
$321,117K
Net cash provided by
(used in) operating...
$24,018K
Effect of exchange rate
changes on cash and cash...
$39K
Canceled cashflow
$276,267K
Canceled cashflow
$43,736K
Canceled cashflow
$67,666K
Net increase
(decrease) in cash, cash...
$891,608K
(19323.98%↑ Y/Y)
Purchase of convertible
senior notes hedge
$195,790K
Repurchase of common stock
$60,000K
Debt discount and
payment of debt issuance...
$20,125K
Taxes paid related to
net share...
$345K
Payments under finance
lease obligations
$7K
Purchases of short-term
investments
$37,148K
Purchases of derivatives
$2,672K
Acquisition of financial
royalty assets
$2,640K
Purchases of other
investments
$1,250K
Purchases of property and
equipment
$26K
Loss from change in
fair value of...
$35,727K
Accounts receivable
$13,850K
(gain) loss from
short-term investments
$11,754K
Non-cash income from
financial royalty assets
$2,068K
(gain) loss on
derivative instruments
$1,369K
Accretion of short-term
investments
$1,199K
Change in estimated
fair value of...
$1,116K
Cecl adjustment to
financial royalty assets
-$222K
Other
-$188K
Income tax receivable
and payable
$173K
Net increase
(decrease) in cash, cash...
$891,608K
Buy us a coffee